The transcription factor E2F-1 is implicated in the activation of S-phase genes as well as induction of apoptosis, and is regulated by interactions with Rb and by cell cycle-dependent alterations in E2F-1 abundance. We earlier demonstrated a pivotal role for poly(ADPribose) polymerase-1 (PARP-1) in the regulation of E2F-1 expression and promoter activity during S-phase re-entry when quiescent cells re-enter the cell cycle. We now investigate the putative mechanism(s) by which PARP-1 may upregulate E2F-1 promoter activity during S-phase re-entry. DNase-1 footprint assays with purified PARP-1 showed that PARP-1 did not directly bind the E2F-1 promoter in a sequence-specific manner. In contrast to p53, a positive acceptor in poly(ADP-ribosyl)ation reactions, E2F-1 was not poly(ADP-ribosyl)ated by wildtype PARP-1 in vitro, indicating that PARP-1 does not exert a dual effect on E2F-1 transcriptional activation. Protein-binding reactions and coimmunoprecipitation experiments with purified PARP-1 and E2F-1, however, revealed that PARP-1 binds to E2F-1 in vitro. More significantly, physical association of PARP-1 and E2F-1 in vivo also occurred in wild-type fibroblasts 5 h after re-entry into S phase, coincident with the increase in E2F-1 promoter activity and expression of E2F-1-responsive Sphase genes cyclin A and c-Myc. Mapping of the interaction domains revealed that full-length PARP-1 as well as PARP-1 mutants lacking either the catalytic active site or the DNA-binding domain equally bind E2F-1, whereas a PARP-1 mutant lacking the automodification domain does not, suggesting that the protein interaction site is located in this central domain. Finally, gel shift analysis with end-blocked E2F-1 promoter sequence probes verified that the binding of PARP-1 to E2F-1 enhances binding to the E2F-1 promoter, indicating that PARP-1 acts as a positive cofactor of E2F-1-mediated transcription.
Introduction
Products of the poly(ADP-ribose) polymerase (PARP) gene family, which now includes PARP-1, -2, -3, v-PARP, and tankyrase (Smith et al., 1998; Ame et al., 1999; Johansson, 1999; Kickhoefer et al., 1999) , catalyse the poly(ADP-ribosyl)ation of various nuclear substrates utilizing NAD as a substrate. These various PARPs exhibit striking homology in their C-terminal catalytic domains, but differ significantly in their N-terminal domains and in their subcellular localizations. PARP-1, the most abundant and most extensively studied member of this family, is activated allosterically by binding to DNA ends and plays essential roles in various nuclear processes Menissier-de Murcia et al., 1989) . PARP-1 undergoes extensive autopoly(ADP-ribosyl)ation in a central automodification domain (Kawaichi et al., 1981; Cherney et al., 1987) . PARP-2 and PARP-3 (Johansson, 1999) apparently account for the residual PARP activity in PARP-1-deficient cells (Shieh et al., 1998; Ame et al., 1999) .
We have shown that PARP-1 is a component of a multiprotein DNA replication complex (MRC; DNA synthesome) that catalyses replication of viral DNA in vitro and contains pol a, pol d, DNA primase, DNA helicase, DNA ligase, topoisomerases I and II, proliferating-cell nuclear antigen (PCNA), replication factor C, and replication protein A (RPA). PARP-1 poly(ADPribosyl)ates 15 of the B40 MRC component proteins, including pol a, topoisomerase I, and PCNA (Simbulan- Rosenthal et al., 1996) , and is also involved in inducing expression of pol a, DNA primase, and RPA (Simbulan- Rosenthal et al., 1998a) . Induction of expression of the transcription factor E2F-1, which positively regulates transcription of genes encoding pol a, PCNA, and other S-phase proteins, is suppressed by PARP-1 depletion by antisense RNA (Simbulan-Rosenthal et al., 1998a) , indicating that PARP-1 plays a role in the expression of these genes during re-entry into the S phase. E2F-1 regulates cell cycle progression, an activity that is regulated by E2F-1 binding to the dephosphorylated form of the tumor suppressor protein Rb; Rb phosphorylation by cyclin-dependent kinases during early S phase releases E2F-1, consequently activating gene expression (Weinberg, 1995) . The loss of cell growth control that underlies the development of human cancers results from perturbation of these control pathways by inactivation of Rb and increased E2F-1 activity. Overexpression of E2F-1 leads to oncogenesis (Johnson et al., 1994a) and drives serum-starved cells through the S phase and into the cell cycle (Johnson et al., 1993) . Deregulated expression of E2F-1 in quiescent cells also leads to S-phase entry followed by p53-mediated apoptosis (Qin et al., 1994) .
We previously clarified the role of PARP-1 in regulation of the expression of pol a and E2F-1 genes during S-phase re-entry of serum-deprived cells, utilizing 3T3 fibroblasts derived from wild-type and PARP-1 À/À mice as well as PARP-1 À/À cells stably transfected with PARP-1 cDNA (PARP-1 À/À ( þ PARP)). A marked increase in pol a transcripts and activity was observed at the peak of S phase in wild-type and PARP-1 À/À ( þ PARP) cells, but not in the PARP-1 À/À cells. E2F-1-promoter reporter assays revealed that PARP-1 regulates the expression of the E2F-1 and pol a genes by stimulating E2F-1 promoter activity (SimbulanRosenthal et al., 1999a) . These data indicate that PARP-1 plays a pivotal role in induction of promoter activity of E2F-1, which positively regulates the transcription of several S-phase genes including those encoding pol a, PCNA, dihydrofolate reductase, thymidine kinase, c-Myc, B-Myb, cyclin A, cyclin E, and E2F-1 itself (Blake and Azizkhan, 1989; Pearson et al., 1991; Nevins, 1992; Slansky et al., 1993; DeGregori et al., 1997) . Depletion of PARP-1 by gene knockout, similar to depletion of the protein by antisense RNA, prevented the increase in the abundance of E2F-1 associated with S-phase re-entry, an effect that is attributable, at least in part, to the lack of induction of E2F-1 promoter activity in the PARP À/À cells. Although the precise mechanisms remain to be elucidated, a converging body of evidence suggests a major involvement of PARP-1 in the regulation of gene transcription. PARP-1 has been shown to play dual roles in transcription, depending on the concentration of NAD and the presence of DNA strand breaks. In the presence of NAD, PARP-1-dependent silencing of transcription involves poly(ADP-ribosyl)ation of specific transcription factors, which prevents both their binding to the respective DNA consensus sequences and the formation of active transcription complexes (Rawling and Alvarez-Gonzalez, 1997; Oei et al., 1998; Butler and Ordahl, 1999; Simbulan-Rosenthal et al., 2001) . Although progress has been made towards understanding the biochemical events that underlie inhibition of transcriptional activation by PARP-1, mechanisms by which this activation can be positively regulated by PARP-1 to ensure a transient transcriptional response remain unclear.
In the absence of NAD, PARP promotes activatordependent transcription by interacting with RNA polymerase II-associated factors (Meisterernst et al., 1997) , transcription enhancer factor 1 (TEF1), and the transcription factor AP-2 to increase the transcription of muscle-specific genes and AP-2-mediated transcription, respectively (Butler and Ordahl, 1999; Kannan et al., 1999) . PARP-1 also functions as a coactivator of Taxactivated transcription in vivo (Anderson et al., 2000) , and is implicated in modulation of transcription of inflammation-linked genes, such as AP-1, SP-1, Oct-1, YY-1, and Stat-1, thus, playing a pivotal role in the initial inflammatory response (Ha et al., 2002) . Alternatively, given that PARP depletion by antisense RNA expression also results in marked changes in chromatin structure, effects of PARP-1 deficiency on gene expression may be attributable, at least in part, to such changes. Reduced levels of poly(ADP-ribosyl)ation have also been shown to result in chromatin compaction and hypermethylation, which inhibits the transcription process (de Capoa et al., 1999) . Some of the functions of PARP-1 may therefore be mediated by direct or indirect effects on gene expression.
In addition, PARP-1, either alone or in a heterodimeric complex with Ku protein, has been shown to specifically bind internal sequences of matrix attachment regions (MARs) (Galande and Kowhi-Shigematsu, 1999 ) that are required for extending chromatin domains and enhancer-distal positions accessible to transcription factors. PARP-1 also interacts and forms complexes with certain internal DNA elements in a sequence-specific manner, including MCAT1 elements in muscle-specific genes, the Reg gene promoter, the CXCL1 gene, and HTLV-1 Tax responsive elements (TxREs) (Butler and Ordahl, 1999; Akiyama et al., 2001; Nirodi et al., 2001; Zhang et al., 2002) , providing a mechanism for PARP-1 transcription regulation in the absence of DNA ends or DNA damage. Thus, the precise mechanism(s) of transcriptional coactivation by PARP-1 remains to be elucidated.
The present study now investigates the potential mechanism(s) by which PARP-1 upregulates E2F-1 promoter activity during re-entry of serum-deprived cells into the S phase. We determined whether PARP plays a direct role in the transcription of E2F-1-responsive genes by binding to E2F-1 promoter sequences or whether PARP-1 stimulates E2F-1 promoter activity by binding to E2F-1, thus acting as a coactivator of E2F-1-mediated transcription. Our results demonstrate for the first time that PARP-1 binds to E2F-1 in vitro as well as in vivo 5 h after re-entry of quiescent cells into the S phase, coincident with the increase in E2F-1 promoter activity and expression of E2F-1-responsive S-phase genes. In addition, the protein interaction site appears to be in the central automodification domain of PARP-1 given that the full-length protein as well as mutants lacking either the catalytic or the DNA-binding domains were equally capable of binding E2F-1, whereas a PARP-1 mutant lacking the automodification domain was not. Moreover, gel shift analysis with end-blocked DNA probes revealed that PARP-1 binds E2F-1 and together, as a complex, augments binding to the E2F-1 promoter region, thus verifying that PARP-1 acts as a positive coactivator of E2F-1-mediated transcription.
Results
Increased expression of E2F-1 and downstream E2F-1-responsive genes cyclin A and c-Myc after S-phase re-entry in wild-type and PARP-1
Utilizing 3T3 fibroblasts derived from wild-type and PARP-1 -/-mice (Wang et al., 1995) , we earlier showed that PARP-1 depletion by gene disruption blocks reentry of cells into the S phase (Simbulan- Rosenthal et al., 1999a) . These PARP-1 -/-cells were previously confirmed to be devoid of immunodetectable PARP-1 and PAR by immunoblot analysis with the corresponding antibodies (Simbulan- Rosenthal et al., 1998b) . Although the presence of other members of the PARP family has been shown in PARP-1 -/-cells, their activity does not fully compensate for PARP-1 depletion (Shieh et al., 1998) . Flow cytometry reveals no significant differences between the DNA histograms of asynchronously growing wild-type and PARP-1 -/-cells. However, when these cells are synchronized by serum deprivation and induced to re-enter the cell cycle by serum addition, wild-type cells, but not PARP-1 -/-cells, exhibit a peak of S phase at 16 h and progress through the cell cycle 24 h after serum addition, verifying a requirement for PARP-1 during S-phase re-entry (Simbulan- Rosenthal et al., 1999a) . Similar to wild-type cells, PARP-1 -/-( þ PARP) cells, synchronously enter the S phase by 14 h and progress through the cell cycle by 22 h. Reintroduction of PARP-1, thus, restores the ability of PARP-1-deficient cells to re-enter the cell cycle after release from serum deprivation.
We verified the effect of PARP-1 deficiency on the abundance of E2F-1 during S-phase re-entry. Similar to our earlier results (Simbulan-Rosenthal et al., 1999a) , immunoblot analysis with antibodies to E2F-1 revealed that both wild-type and PARP-1 -/-( þ PARP) cells exhibit a marked increase in E2F-1 abundance as early as 2 h after release from serum deprivation (Figure 1a) , consistent with the fact that the E2F-1 gene is an early response gene (Johnson et al., 1994b) .
E2F-1 protein levels remained elevated for 16 h in these cells. PARP-1 -/-cells, however, contained negligible amounts of E2F-1 for up to 16 h ( Figure 1a ) and thereafter (24 h after serum addition; data not shown). PARP-1 depletion by antisense RNA expression in 3T3-L1 cells also prevents induction of E2F-1 expression during the early stages of differentiation-linked DNA replication (Simbulan-Rosenthal et al., 1998a) . The induction of downstream target genes of E2F-1, such as cyclin A and c-Myc (Figure 1b and c) , occurred subsequent to that of E2F-1 at 5-7 h after serum addition in wild-type and PARP-1
-/-cells, consistent with their being encoded by late-response genes (Pearson et al., 1991) . As an internal control, the expression of PCNA remained at high levels at all time points tested in the PARP-1 (Figure 1d ), thus, discounting the possibility that lack of induction of E2F-1, cyclin A, and c-Myc in these cells was attributable to a general inability to undergo protein or RNA synthesis. These results suggest that PARP-1 may partially regulate the expression of cyclin A and c-Myc genes during early S phase by increasing the expression of the E2F-1 gene itself.
E2F-1 is not poly(ADP-ribosyl)ated by wild-type PARP-1 in vitro
We have previously shown that PARP-1 upregulates pol a and E2F-1 expression at the level of transcription during early S phase (Simbulan-Rosenthal et al., 1999a) . silencing of transcription involves poly(ADP-ribosyl) ation of a number of transcription factors, which prevents the formation of active transcription complexes (Oei et al., 1998) . The basal transcription factors TFIIF and TEF-1 as well as transcription factors TBP, YY1, SP-1, and CREB, but not c-Jun or AP-2, are all highly specific substrates for poly(ADP-ribosyl)ation (Rawling and Alvarez-Gonzalez, 1997; Oei et al., 1998; Butler and Ordahl, 1999) . Modification of these proteins prevents binding to their respective DNA consensus sequences (Oei et al., 1998) . We therefore determined whether PARP-1 can poly(ADP-ribosyl)ate E2F-1 in vitro.
Full-length human E2F-1 cDNA in a plasmid construct (E2F-1-pCDNA3; DeGregori et al., 1997) was used to synthesize E2F-1 protein by coupled T7 RNA polymerase-mediated transcription and translation. Immunoblot analysis of the transcription/ translation products from E2F-1/pcDNA3-and vector-containing reactions revealed the presence of a 60-kDa immunoreactive protein corresponding to fulllength E2F-1 (Figure 2a ). E2F-1 protein was then incubated with either purified recombinant PARP-1 or a catalytically inactive Lys893 mutant and NAD, in a standard poly(ADP-ribosyl)ation reaction. Wild-type PARP-1 and the Lys893 PARP-1 mutant have been previously characterized and described (Kim et al., 1997; Simbulan-Rosenthal et al., 2001) . As expected, although both proteins are full length, the wild-type PARP-1 protein was catalytically active (1.9 Â 10 3 nmol/min per mg), whereas the mutant PARP-1 was not (8 nmol/ min per mg), as verified by incorporation of [ 32 P]NAD into acid-insoluble acceptors.
E2F-1 (1 mg) was incubated in the presence of 100 mm NAD, nicked DNA, and either wild-type or mutant PARP-1 (0.1 mg), and subjected to immunoblot analysis with anti-PAR to confirm presence of PAR chains on the proteins. Immunoreactive proteins of 4114 kDa correspond to automodified PARP-1, given that these bands were also observed in reactions containing wildtype PARP-1 alone and NAD, but not in those with mutant PARP-1 (Figure 2b left panel) . Reprobing of the immunoblot with antibodies to E2F-1 revealed a B60-kDa band, distinct from the 4114 kDa band detected with anti-PAR (Figure 2 right panel), thus, indicating that the modified protein was not E2F-1. PARP-1 is the main acceptor in these reactions, attributable to the presence of up to 28 automodification sites in the protein (Kawaichi et al., 1981; Cherney et al., 1987; Desmarais et al., 1991) . In contrast to E2F-1, we have demonstrated that GST-p53 is an effective substrate for PARP-1 under the same conditions (Simbulan- Rosenthal et al., 2001) .
When the reaction mixture was depleted of PARP-1 and subjected to immunoprecipitation with antibodies to E2F-1, immunoblot analysis with anti-PAR failed to detect any specific immunoreactivity (Figure 2c left panel), verifying that E2F-1 is not a substrate for poly(ADP-ribosyl)ation by PARP-1. Reprobing of the immunoblot with anti-E2F-1 confirmed that E2F-1 is present but remains unmodified in the presence of PARP-1 and NAD (Figure 2c , right panel). In contrast, GST-p53 is extensively poly(ADP-ribosyl)ated by wildtype PARP-1, as shown by immunoprecipitation experiments with anti-p53 followed by immunoblot analysis with anti-PAR (Simbulan- Rosenthal et al., 2001) . Consistently, E2F-1 was not modified by PARP-1 in vivo, as shown by the lack of immunoreactivity when nuclear extracts of wild-type and PARP-1 -/-cells, synchronized by serum starvation and released into early, mid-, and late S phase, were immunoprecipitated In vitro-translated E2F-1 protein (1 mg) and a translation reaction lacking E2F-1 (vector) (30 mg) were subjected to immunoblot analysis with antibodies to E2F-1. (b) Wild-type or mutant PARP-1 (0.1 mg) was incubated for 30 min at 371C in the presence of 100 mm NAD and E2F-1 (1 mg), as indicated. The reaction mixtures were then subjected to immunoblot analysis with anti-PAR, after which the blots were stripped of antibodies and reprobed with anti-E2F-1. (c) E2F-1 was incubated in the absence or presence of wild-type or mutant PARP-1 as in (b). The reaction mixtures were immunodepleted of PARP-1 and then subjected to immunoprecipitation (IP) with anti-E2F-1 or with control IgG, as indicated. The resulting immunocomplexes were subjected to immunoblot analysis (IB) with anti-PAR; the blots were then stripped of antibodies and reprobed with antibodies to E2F-1 E2F-1 physically associates with PARP-1 CM Simbulan-Rosenthal et al with anti-E2F-1 and subjected to immunoblot analysis with anti-PAR (data not shown). Similar experiments were performed previously to establish poly(ADP-ribosyl)ation of p53 at the early stages of apoptosis in human osteosarcoma cells (SimbulanRosenthal et al., 1999b) .
PARP-1 does not bind the E2F-1 promoter in a sequence-specific manner as shown by DNase-1 footprint analysis
Given that PARP-1 interacts with certain DNA elements in a sequence-specific manner, including MCAT1 elements (Butler and Ordahl, 1999) , the Reg gene promoter (Akiyama et al., 2001) , the IUR element in the CXCL1 gene (Nirodi et al., 2001) , and HTLV-1 TxREs (Zhang et al., 2002) , we determined whether PARP-1 plays a direct role in the transcription of E2F-1 genes by binding to the E2F-1 promoter sequence. To map binding sites of PARP-1 to the E2F-1 promoter, this region was excised from the E2F-1 promoterluciferase construct used earlier and end-labeled with [ 32 P]dATP. DNase 1 footprint analysis utilizing these linear E2F-1 promoter probes revealed that PARP-1 does not bind the internal E2F-1 promoter region in a sequence-selective manner ( Figure 3 , lane 2). In contrast, both E2F-1 and an E2F-1/PARP-1 mixture bound the same internal regions of the E2F-1 promoter sequence, as shown by the presence of the same protected regions against DNase I digestion. Preincubation of PARP-1 with E2F-1 slightly altered the DNase I protection pattern of E2F-1, enlarging the protected region in site 2 (Figure 3, lanes 3 and 5) . Binding of AP-1 to its corresponding sequence element verified the specificity of the assay (lanes 6 and 7). PARP-1 therefore does not activate the transcription of E2F-1 genes by directly binding to E2F-1 promoter sequences.
PARP-1 physically associates with E2F-1 in vitro as revealed by protein-binding reactions and coimmunoprecipitation experiments
Given that PARP-1, in the absence of NAD, coactivates transcription by binding transcription factors, we investigated whether PARP-1 modulates E2F-1-mediated transcription by binding to E2F-1, and whether physical association of the two proteins, as with the other transcription factors, enhances binding to the E2F-1 consensus sequence. In vitro protein-binding reactions were carried out by incubating 1 mg each of E2F-1 and PARP-1 for 1 h on ice; the reactions were then subjected to coimmunoprecipitation with antibodies to E2F-1. Immunoblot analysis of the resulting precipitates with anti-PARP-1 revealed binding of PARP-1 to E2F-1 in vitro (Figure 4a ; left panel) in reactions containing both proteins, but not in those lacking E2F-1 (vect). Reprobing the immunoblot with anti-E2F-1 verified the presence of E2F-1 in the immunocomplexes with PARP-1 (Figure 4a , right panel). When reactions were immunoprecipitated with control IgG, however, immunoblot analysis with antibodies to E2F-1 or to PARP-1 failed to detect any immunoreactivity, thus, confirming the specificity of binding. As a positive control, GST-p53, which has previously been shown to physically associate with PARP-1, was also preincubated with PARP-1, and subjected to immunoprecipitation with anti-p53 (Figure 4b ). Similar to E2F-1, immunoblot analysis of the precipitates with anti-PARP-1 showed binding of PARP-1 to GST-p53 in vitro (left panel), and reprobing N o p r o te in N o p r o te in P A R P A P 2 E 2 F -1 R e ti c , ly s a te E 2 F -1 + P A R P 1 2 3
Figure 3 PARP-1 does not bind directly to the E2F-1 promoter region in a sequence-specific manner as revealed by DNase-1 footprint analysis. The E2F-1 promoter region was excised from the E2F-1-luc construct pGL2 and end-labeled with [ 32 P]dATP. DNase-1 footprint assays were then performed with these E2F-1 probes in the presence of PARP-1, E2F-1, or E2F-1 þ PARP-1, according to standard procedures. As a positive control for the assay, AP-2 specific probes were also incubated with AP-2 and subjected to DNase-1 fooprint assays. The DNase I-treated protein-DNA complexes were then analysed by electrophoresis on sequencing gels, followed by autoradiography. PARP-1 binds E2F-1 in vivo in wild-type fibroblasts by 5 h after S-phase re-entry, coincident with the increase in E2F-1 promoter activity
Having demonstrated binding of E2F-1 to PARP-1 in vitro, we next investigated whether this binding also occurs in cells, and whether the binding of E2F-1 by PARP-1 in vivo coincides with the marked increase in E2F-1 promoter activity during early S phase. Coimmunoprecipitation experiments were performed utilizing nuclear extracts from wild-type cells that were synchronized by serum deprivation and harvested at 0, 2, 5, 7, and 16 h after serum addition. Nuclear extracts were immunoprecipitated with antibodies to E2F-1, and the immunocomplexes were subjected to immunoblot analysis with mAb to PARP-1. Endogenous levels of PARP-1 bound to E2F-1 was first evident at 5 h, and increased thereafter up to 16 h after S-phase re-entry ( Figure 5, upper panel) . Reprobing the blot with anti-E2F-1 confirmed marked induction of E2F-1 expression 2 h after serum addition ( Figure 5 , lower panel), although no PARP-1-E2F-1 binding was apparent at this time. Subsequently, E2F-1 levels increased markedly, concomitant with binding of E2F-1 to PARP-1. On the other hand, no nonspecific binding of PARP-1 was apparent when immunoprecipitation was performed with control IgG. The observation that PARP-1 is specifically bound to E2F-1 after re-entry of quiescent cells into the S phase suggests that this protein-protein interaction may be involved in the upregulation of E2F-1 promoter activity. We previously showed that, when wild-type, PARP-1 -/-and PARP-1 -/-( þ PARP) cells were transfected with E2F-1 promoter-luciferase reporter constructs and induced to re-enter S phase by serum addition, elevation of E2F-1 promoter activity occurred at 5 h and peaked by 9 h in both wild-type and PARP-1 -/-( þ PARP) cells (Simbulan-Rosenthal et al., 1999a) . The induction of E2F-1 promoter activity coincides with the physical association of PARP-1 and E2F-1 at 5 h after S-phase re-entry ( Figure 5 ). In contrast, E2F-1 promoter activity in PARP-1 -/-cells showed no increase (SimbulanRosenthal et al., 1999a) , suggesting that PARP-1 may upregulate expression of E2F-1 and its downstream targets by binding to E2F-1, consequently stimulating the activity of the E2F-1 gene promoter. Correlation of the time course of PARP-1-E2F-1 binding during Sphase re-entry ( Figure 5 ) with the induction of expression of the E2F-1-responsive genes cyclin A and c-Myc (Figure 1 ) likewise revealed expression of cyclin A and c-Myc 5-7 h after serum addition, concomitant with PARP-1-E2F-1 binding as well as the elevation of E2F-1 promoter activity. Although E2F-1 levels were already significantly elevated by 2 h, the lack of both PARP-1-E2F-1 binding and expression of E2F-1 responsive genes at this time, suggests that this protein-protein binding plays an essential role in the induction of E2F-1 promoter activity.
Full-length PARP-1 and mutants lacking the catalytic active site or the DNA-binding domains equally bind E2F-1, whereas a mutant lacking the automodification domain does not Full-length PARP-1 encompasses three functional domains, the C-terminal catalytic domain (CAT), the (1 mg; a), a translation reaction lacking E2F-1 (vector alone; 30 mg; a) or p53 (1 mg; b) was incubated with PARP-1 for 1 h on ice, and then subjected to coimmunoprecipitation experiments with antibodies to E2F-1, to p53, or with control IgG, as indicated. The resulting immunoprecipitates were then subjected to immunoblot analysis with antibodies to PARP-1 (left panels). The blots were stripped of antibodies and subsequently reprobed with antibodies to E2F-1 (a) or to p53 (b) Figure 5 Physical association of PARP-1 and E2F-1 in vivo occurs 5 h after S-phase re-entry, coincident with the increase in E2F-1 promoter activity. At the indicated times after re-entry of quiescent cells into the S phase, cell extracts were prepared and equal amounts of total protein (100 mg) were subjected to immunoprecipitation with a mAb to E2F-1. The immunoprecipitated proteins were then subjected to immunoblot analysis with anti-PARP-1 (upper panel). In control experiments with extracts derived from the 7 h time point, immunoprecipitation was performed with control IgG (preimmune serum). The minor band below the PARP-1 band corresponds to a nonspecific band. The immunoblot was reprobed with antibodies to E2F-1 (lower panel). The positions of PARP-1 and E2F-1 are indicated E2F-1 physically associates with PARP-1 CM Simbulan-Rosenthal et al N-terminal DNA-binding domain (DBD), and the central automodification domain (AD) (Figure 6a ). To further map the interaction domains in PARP-1 and E2F-1, we performed protein-binding experiments using full-length PARP-1 as well as truncation mutants lacking the C-terminal catalytic active site, the DBD, or the DBD-AD of the protein. CMV-Myc tagged PARP-1 expression vectors with full-length PARP cDNA (PARP-fl) or truncation mutants (DBD-ADpartCAT(-p 1À829 ), AD-CAT(-p 338À1014 ), CAT(-p 525À1014 ); (Hassa et al., 2001) ) were used to synthesize wild-type and mutant PARP-1 by in vitro transcription and translation. Immunoblot analysis of the products with antibodies to the c-Myc epitope confirmed the presence of 120-, 94-, 74-, and 54-kDa immunoreactive proteins corresponding to full-length PARP-1 and truncated products lacking the catalytic active site, DBD, or DBD-AD of PARP-1 (lanes 1-4, respectively) (Figure 6b ). Full-length or truncated PARP-1 was preincubated with E2F-1, and subjected to coimmunoprecipitation with anti-E2F-1. Immunoblot analysis of the precipitates with anti-Myc revealed that, while full-length PARP-1 as well as mutants lacking either the active site or the DBD equally bound E2F-1 (Figure 6c, lanes 1-3,  respectively) , the mutant lacking the DBD-AD did not (Figure 6c, lane 4) , indicating that the protein interaction site is located in the central AD. Consistently, this central AD of PARP-1 includes a BRCT domain that has been implicated in interactions with various other proteins, including XRCC1 (Masson et al., 1998) , HPV18 E2 (Lee et al., 2002) , and NF-kB p50 and p65 (Hassa et al., 2001) . Binding of PARP-1 to E2F-1 and induction of E2F-1 promoter activity during S-phase reentry is therefore independent of the DNA binding or enzymatic activity of PARP-1, consistent with our results showing that PARP-1 neither binds internal sequences of the E2F-1 promoter nor modifies E2F-1 by poly(ADP-ribosyl)ation.
Physical association of PARP-1 and E2F-1 in vitro enhances binding to the E2F-1 promoter sequence, acting as a novel coactivator of transcription To investigate whether binding of PARP-1 to E2F-1 alters E2F-1 binding to its promoter sequence element, we performed electrophoretic mobility shift assays (EMSA) with [ 32 P]dCTP-biotinylated oligonucleotides containing the E2F-1 DNA consensus sequences. Since PARP-1 binds DNA ends, gel shift assays were performed with end-blocked probes. After preincubation with streptavidin (SA) to block the DNA ends, the probes were incubated with excess poly(dI : dC) and BSA. PARP-1-E2F-1 protein-binding reactions were then incubated with the end-blocked DNA probes and DNA-protein complexes were then analysed by electrophoresis and autoradiography as described in Materials and methods.
Binding of free E2F-1 to the specific probe was apparent by the appearance of a distinct shifted band corresponding to the E2F-1-DNA complex (Figure 7 , lane 3). Significantly, preincubation of PARP-1 with E2F-1 markedly enhanced the binding of the PARP-1-E2F1 complex to the specific DNA probe (lane 4). The shifted bands were not due to binding of unbound PARP-1 to DNA ends or breaks in the probe because PARP-1, in the absence of E2F-1, failed to bind the E2F-1 probe (lane 2). The specificity of the interaction was also confirmed by inhibition of E2F-1 binding to the probe in the presence of excess nonradioactive-specific probe (data not shown). Altogether, these results 
Discussion
Depletion of PARP-1 by antisense RNA expression or by gene disruption blocks quiescent cells from reentering the cell cycle after recovery from serum deprivation, and stable transfection of PARP-1 À/À cells with PARP-1 cDNA restores the ability of these cells to re-enter the cell cycle (Simbulan- Rosenthal et al., 1998a Rosenthal et al., , 1999a . PARP-1 deficiency also prevents the induction of pol a and E2F-1 gene expression that normally occurs during early S phase under these conditions (Simbulan- Rosenthal et al., 1999a) . In response to growth stimulation, E2F-1 activates the promoters of the pol a and other S-phase genes, and also activates transcription of its own gene during the cell cycle by binding to E2F binding sites in the E2F-1 gene promoter (Neuman et al., 1994) . The increase in pol a transcripts and activity as well as E2F-1 expression in wild-type and PARP-1
cells, suggests that PARP-1 plays a role in the induction of E2F-1 promoter activity during early S phase.
In the present study, we investigated the putative mechanism(s) by which PARP-1 may upregulate E2F-1 promoter activity during re-entry of serum-deprived cells into the S phase. We first demonstrated by DNase I footprinting assays that PARP-1 does not play a direct role in the transcription of pol a and E2F-1 genes by binding to internal E2F-1 promoter sequences and acting as a transcription factor itself, unlike its sequence-specific interaction with other DNA elements such as MCAT1 elements, the Reg gene promoter, the IUR element in the CXCL1 gene, and HTLV-1 TxREs (Butler and Ordahl, 1999; Akiyama et al., 2001; Nirodi et al., 2001; Zhang et al., 2002) . PARP-1 has been shown to behave as either an inhibitor or activator of bound transcription factors, depending on the presence of specific binding partners, the proliferative status of the cell, and the presence of NAD. PARP-1, in the absence of NAD, enhances activator-dependent transcription by interacting with an increasing number of transcription factors, including AP-2, Oct 1, NF-kB, and p53 (Meisterernst et al., 1997; Nie et al., 1998; Butler and Ordahl, 1999; Hassa and Hottiger, 1999; Kannan et al., 1999; Oliver et al., 1999; Wesierska-Gadek et al., 2003) . We thus determined whether PARP-1 upregulates E2F-1 expression and promoter activity during S-phase reentry by binding to E2F-1, thus acting as a coactivator of E2F-1-mediated transcription. Our results provide evidence for the first time that PARP-1 physically associates with E2F-1 in vitro as well as in vivo 5 h after S-phase re-entry. This interaction coincides with the elevation of E2F-1 promoter activity and expression of E2F-1-responsive S-phase genes, such as pol a, cyclin A, and c-myc. Although E2F-1 accumulation was already significantly elevated by 2 h, the lack of both PARP-1-E2F-1 binding and E2F-1 promoter activity as well as expression of E2F-1-responsive genes cyclin A and c-myc at this time suggests that this protein-protein interaction plays a role in the induction of E2F-1 promoter activity.
Full-length PARP-1 as well as mutants lacking either the catalytic active site or the DBD were equally capable of binding E2F-1, whereas a mutant lacking the AD was not, thus indicating that the protein-binding site maps to the central AD. This central domain of PARP-1 encompasses a BRCT (BRCA1 C-terminus) motif (aa 372-476) involved in interactions with other proteins, including PARP itself, histones (Buki et al., 1995) , XRCC1 (Masson et al., 1998) , Oct 1 (Nie et al., 1998) , HPV18 E2 (Lee et al., 2002) , NF-kB p50 and p65 (Hassa et al., 2001) , and p53 (Wesierska-Gadek et al., 2003) . Comprising about 100 residues, this BRCT motif is ubiquitous in other proteins involved in DNA repair and cell cycle checkpoints, including XRCC1, DNA ligase III (Nashh et al., 1997) , XRCC4, DNA ligase IV (Critchlow et al., 1997) , and p53 (Yamane et al., 2001) , and represents an interface for multimerization and specific protein-protein contacts between protein pairs. Our results showing that PARP-1 neither binds internal sequences of the E2F-1 promoter nor modifies E2F-1 by poly(ADP-ribosyl)ation is consistent with the fact that PARP-1-E2F-1 binding does not require the DNAbinding domain or the catalytic active site of PARP-1. In addition, the observation that E2F-1 is not a substrate for modification by PARP-1 indicates that the enzyme does not exert a dual effect on E2F-1 transcriptional activation. Finally, our results with gel shift analysis using end-blocked DNA probes provide evidence that PARP-1 physically associates with E2F-1 and together, as a complex, exhibits enhanced binding to the E2F-1 promoter region. These results altogether verify that PARP-1 plays a role as a positive coactivator of E2F-1-mediated transcription.
Similar to E2F-1, protein-protein interaction between NF-kB p65 and PARP-1 requires neither the DNA binding nor the enzymatic activity of PARP-1 for its coactivator function (Hassa et al., 2001) . PARP-1 also enhances the transactivation of B-Myb, another transcription factor implicated in cell growth control, differentiation, and cancer, independently of PARP-1 enzymatic activity (Cervellera and Sala, 2000) . Given that binding sites for E2F-1 are also present in b-myb promoters (Lam et al., 1995) , it is possible that, in addition to direct binding of PARP-1 to B-Myb, PARP-1 can induce b-myb transcription by its coactivation of E2F-1. cyclin A also represents one of the E2F-1-responsive genes during S-phase re-entry (Shan et al., 1996) , and controls cell cycle progression by associating with and regulating the activities of cyclin-dependent kinases (Pagano et al., 1992; van den Heuvel and Harlow, 1993; Furuno et al., 1999) . Our results suggest that PARP-1 may upregulate cyclin A expression via its coactivation of E2F-1-mediated transcription during early S phase. Consistently, microarray analysis to characterize the differences in gene expression between PARP-1 -/-and wild-type primary fibroblasts revealed that PARP-1 deficiency results in downregulation of a subset of genes that contribute to regulation of cell cycle progression or mitosis, including cyclin A (Simbulan- .
In preliminary studies, we also determined whether PARP-1 can poly(ADP-ribosyl)ate and, consequently, affect binding of other factors that normally bind E2F-1, such as Rb, which mediates the precise regulation of E2F-1 transactivation during the cell cycle. Rb phosphorylation by cyclin-dependent kinases in mid-to late G1 determines dissociation from E2F-1, and consequent transcriptional activation of E2F-1-responsive genes, as well as progression through the cell cycle (Knudsen and Wang, 1997) . Rb cDNA derived from pHBApr-1-neoRb (Tang et al., 1989) was subcloned into pCDNA3 (Invitrogen) and used to synthesize full-length Rb protein by in vitro transcription and translation. Similar to E2F-1, Rb protein was not a substrate for poly(ADPribosyl)ation by PARP-1. Interestingly, PARP-1 also bound Rb in vitro as revealed by coimmunoprecipitation experiments (data to be published elsewhere). Whether this interaction occurs in vivo and the effects of the interaction between PARP-1 and Rb on E2F-1-Rb binding, however, remains to be clarified.
In conclusion, we have provided evidence for physical association of PARP-1 and E2F-1 in vitro as well as in vivo 5 h after re-entry of quiescent cells into the S phase, concurrent with the increase in E2F-1 promoter activity and expression of E2F-1-responsive S-phase genes cyclin A and c-myc. The increase in E2F-1 promoter activity, as well as expression of E2F-1 and its downstream target genes are prevented in PARP-1-deficient cells, verifying a role for PARP-1 in E2F-1-mediated transcriptional activation of S-phase genes. Finally, the interaction of PARP-1 and E2F-1 increases the binding affinity of E2F-1 to its consensus sequence, independently of the DNA binding or enzymatic activity of PARP-1, indicating that it enhances transactivation of E2F-1-responsive promoters by acting as a positive cofactor for E2F-1-mediated transcription. This represents a novel mechanism of regulation of E2F-1, in addition to repression of the transactivation domain by Rb protein (Knudsen and Wang, 1997) and acetylation by histone p300 cEBP acetyltransferases (Marzio et al., 2000) .
Materials and methods

Cells, vectors, and transfection
Wild-type and PARP-1 À/À fibroblasts, immortalized by a standard 3T3 protocol, were kindly provided by ZQ Wang (International Agency for Research on Cancer, Lyon, France), grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS), penicillin (100 U/ml), and streptomycin (100 mg/ml), and subcultured every 4 days. PARP-1 À/À fibroblasts were transfected with a plasmid encoding wild-type human PARP-1 (pCD12; ) utilizing lipofectamine (Life Technologies). Stable transfectants were selected in growth medium containing zeocin (500 mg/ml). The expression of PARP-1 was confirmed by RNA, DNA, and immunoblot analysis of control and stably transfected cell lines (Simbulan-Rosenthal et al., 1998b) .
Cell synchronization and release into S phase
Cells were plated at a density of 10 5 cells per plate 24 h prior to synchronization at the G1/S transition by serum deprivation. Cells were washed twice with PBS and incubated for 30-45 h in DMEM supplemented with 0.5% FBS, after which the quiescent cells were stimulated to proliferate by incubation in DMEM containing 15% FBS. Cell cycle analysis by flow cytometry was carried out to confirm re-entry into the cell cycle, as previously described (Simbulan-Rosenthal et al., 1999a) .
In vitro transcription and translation of E2F-1; wild-type and mutant PARP-1
The full-length E2F-1 protein was synthesized in vitro by T7 RNA polymerase-mediated transcription and translation (Promega) and immunoaffinity-purified. Recombinant human wild-type PARP-1 and Lys893 PARP-1 mutant, a kind gift from Alexander Spoonde, were expressed as six histidinetagged fusion protein in E. coli, purified to 495% homogeneity by Ni-resin column chromatography, and renatured as previously described (Rosenthal et al., 1997; Smulson et al., 1998) .
In vitro transcription and translation of Myc-tagged full-length PARP-1 and its truncation mutants CMV-Myc tagged PARP-1 expression vectors with full-length PARP-1 cDNA (PARP-fl) or truncation mutants (DBD-ADpartCAT (-p 1À829 ), AD-CAT(-p 338À1014 ), CAT(-p 525À1014 )) were generated as previously described (Hassa et al., 2001) , with a strong Kozak sequence introduced in front the PARP-1 gene in pCDNA3 by PCR and a Myc oligonucleotide inserted into the Nco site downstream of the first ATG. The full-length PARP-1 and its truncation mutants were then synthesized in vitro by T7 RNA polymerase-mediated transcription and translation in a reticulocyte lysate system (Promega).
DNase I footprint assays
To map sites of binding of PARP-1 to the E2F-1 promoter, this region was excised from the E2F-1 promoter-luciferase construct and labeled with [g-32 P]ATP. DNase 1 footprint analysis was then performed with these linear E2F-1 promoter probes, using the Core Footprinting System (Promega) according to standard procedures. The binding solutions contained 100 fmol of labeled probe and E2F-1, PARP-1 or a reaction with PARP-1-E2F-1 (1 mg each) in a binding buffer containing 10 mm Tris-HCl pH 7.5, 40 mm NaCl, 1 mm dithiothreitol, and 1 mg poly(dI-dC). Binding reactions were carried out for 10 min on ice in a final volume of 50 ml; DNA was then digested with 0.3 U RQ1-DNase in the presence of Ca 2 þ /Mg 2 þ for 1 min at RT, extracted with phenol/chloroform and ethanol, and subjected to electrophoresis on 6% polyacrylamide sequencing gels and autoradiography.
Poly(ADP-ribosyl)ation of E2F-1 in vitro by purified recombinant PARP-1 E2F-1 (1 mg) was incubated for 30 min at 371C with purified recombinant wild-type PARP-1 (0.1 mg) in a reaction mixture (50 ml) containing 50 mm Tris-HCl (pH 7.8), 25 mm MgCl 2 , 1 mm dithiothreitol, 4 mg of nicked calf thymus DNA, and 100 mm NAD. The reaction was terminated by the addition of SDS-polyacrylamide gel electrophoresis (PAGE) sample buffer, and the resulting mixture was subjected to immunoblot analysis with anti-PAR. Poly(ADP-ribosyl)ation of E2F-1 was also assessed by incubation of these proteins for 1, 3 or 5 min at 371C in the same reaction mixture but containing 1 mm [ 32 P]NAD (1 mm) in place of 100 mm NAD; the mixtures were subsequently analysed by SDS-PAGE and autoradiography.
Electrophoretic mobility-shift assay (EMSA)
EMSA analysis was performed according to standard procedures. Oligonucleotides containing the E2F-1 consensus binding sequences were biotinylated at the 5 0 end, with a bottom strand complementary to the top strand except for the G at the 3 0 end for labeling. Complementary oligonucleotides were heated to 981C, slow-cooled to anneal, and gel-purified in a 12% polyacrylamide gel. The probe was labeled with [ 32 P]dCTP by Klenow's fragment of PolI, and purified by G-25 spin column. For binding assays, 90 fmol of labeled probe was preincubated with 50 pmol of streptavidin (Sigma) at RT for 5 min to block the DNA ends. The SA probes were incubated with excess poly(dI : dC) (10 mg) and BSA (10 mg) in DNA binding buffer (Promega). In total, 70 pmol each of E2F-1, PARP-1, or PARP-1-E2F-1 protein-binding reactions was incubated with the 32 P-labeled DNA probe (100 000 c.p.m.) in a final volume of 20 ml for 15 min at RT. The DNA-protein complexes were then analysed by electrophoresis on native 5% polyacrylamide gels in Tris-borate-EDTA buffer, followed by autoradiography.
Immunoprecipitation and immunoblot analysis
Immunoblot analysis, SDS-PAGE, and transfer of proteins to nitrocellulose membranes were performed according to standard procedures. The membranes were stained with Ponceau S (0.1%) to confirm equal loading and transfer of proteins, and were then incubated, unless indicated otherwise, with mouse monoclonal antibodies (mAbs) to PAR (1 : 250 dilution; (Kawamitsu et al., 1984) ) or with rabbit polyclonal antibodies to the E2F-1 (1 : 200 dilution; Santa Cruz Biotech), to PARP-1 (1 : 1000 dilution; Pharmingen). Immune complexes were detected with appropriate horseradish peroxidase-conjugated secondary antibodies (1 : 3000 dilution) and enhanced chemiluminescence (Pierce).
Immunoprecipitation was carried out as described (Simbulan- Rosenthal et al., 2001) . Equal amounts of protein binding mixtures or of cell extracts (100 mg protein) were incubated for 30 min at 41C in a final volume of 200 ml containing EBC buffer (50 mm Tris-HCl (pH 8.0), 120 mm NaCl, 0.5% NP-40, aprotinin (0.1 TIU/ml)), 1 mg of control mouse or rabbit (as appropriate) immunoglobulin G (IgG), and 20 ml of protein A/ G-agarose beads (Pharmacia). After removal of the beads by centrifugation, immunoprecipitation was performed by incubation of supernatants for 1 h at 41C in a final volume of 500 ml containing NET-N buffer (20 mm Tris-HCl (pH 8.0), 100 mm NaCl, 1 mm EDTA, 0.5% NP-40) and rabbit polyclonal antibodies to E2F-1 conjugated to protein A/G-agarose beads (1 mg; Santa Cruz Biotech) in Tris-buffered saline containing 10% (w/v) BSA, and the mixtures were incubated for an additional 1 h at 41C. The beads were then separated by centrifugation and washed extensively with NET-N buffer, after which the bound proteins were subjected to immunoblot analysis, first with the mAb to E2F-1 and then with antibodies to PARP-1.
Abbreviations DMEM, Dulbecco's modified Eagle's medium; FBS, fetal bovine serum; MRC, multiprotein DNA replication complex; PARP, poly(ADP-ribose) polymerase; PAR, poly(ADPribose); PBS, phosphate-buffered saline; PCNA, proliferating-cell nuclear antigen; pol, DNA polymerase; RFC, replication factor C; RPA, replication protein A; BRCT, breast cancer susceptibility protein C-terminus.
